喉鳞状细胞癌患者Th1/Th2转录因子与细胞因子的表达及其临床意义探讨

Expression of Th1/Th2 transcription factors and cytokines in laryngeal sqamous cell carcinoma and its clinical significance

目的:从转录因子与细胞因子的角度分析喉鳞状细胞癌患者Th1/Th2细胞分化趋势,探讨T-bet/GATA3与p53的相关性,了解其与肿瘤转移之间的关系。方法:利用荧光定量PCR技术检测49例喉鳞状细胞癌患者(实验组)及30例正常人(正常对照组)外周血单个核细胞(PBMC)中T-bet、GATA3和IFN-γ、IL-4mR-NA的水平;应用免疫组织化学法检测实验组中p53的表达状况。结果:实验组T-bet、GATA3、IFN-γ、IL-4的表达率依次为42.86%(21/49)、71.43%(35/49)、26.53%(13/49)、63.27%(33/49)。定量PCR结果显示,实验组的T-bet和IFN-γ的表达明显低于正常对照组(P<0.05),而GATA3和IL-4的表达则明显高于正常对照组(P<0.05)。在p53阳性的患者中,T-bet的表达量较低,而GATA3的表达量较高,且T-bet和GATA3的表达与p53具有相关性。结论:喉鳞状细胞癌患者有明显的Th2漂移现象,且T-bet与GATA3可作为反映肿瘤转移的参考指标。

Objective：To study the differentiation of Th1/Th2 on the levels of transcription factors and cytokines production in patients with laryngeal sqamous cell carcinoma in peripheral blood mononuclear cells（PBMC）.In addition,the relation of p53 and T-bet,GATA3 expression was discussed for understanding the role of T-bet and GATA3 in metastasis.Method：The gene expression of Th1/Th2 type transcription factors T-bet,GATA3 and cytokines IFN-γ,IL-4 were determined by RT-PCR and realtime RT-PCR from 49 patients with laryngeal sqamous cell carcinoma and 30 normal controls.The expression of p53 was analyzed by immunohistochemistry.Result：Predominant expression of Th2 type cytokines was detected in 49 laryngeal sqamous cell carcinoma patients.The expression rates of T-bet,GATA3,IFN-γ and IL-4 was 42.86%（21/49）,71.43%（35/49）,26.53%（13/49）,63.27%（33/49） respectively.The expression rates of T-bet and IFN-γ in patients were lower than in control group（P〈0.05）,but the results of GATA3 and IL-4 were opposite（P〈0.05）.The similar results were obtained by realtime PCR.The expression of p53 in patients was accompanied with lower expression of T-betmRNA and higher expression of GATA3mRNA.Conclusion：There is predominant expression of Th2 type transcription factors and cytokines in PBMC of laryngeal sqamous cell carcinoma patients.T-bet and GATA3 can be used as reference indicators for the metastasis of laryngeal sqamous cell carcinoma.